供应商 · 生产商 · 工业生物技术与生物基材料
Novonesis
诺和新元（Novonesis）相信根植于生物学的方案是应对世界挑战的关键：酶、功能蛋白和微生物是地球上最小却最强大的变革力量——以科学释放其能力，创造改变生产、消费和生活方式的生物方案。公司现有全球员工 10,000 名，专长覆盖 30 多个行业；生物方案已为数千客户创造价值，让供养与供能世界更可持续（从健康可持续的营养到生物燃料），并减少化石资源、化学品、能源和水的使用。
简介
供应的生物解决方案 1
| D2E2 | 以洗涤剂用酶实现低温洗涤，替代磷酸盐、额外表面活性剂和热水洗涤 |
已核实的产品关联: Denimax → T02; Lipozyme interesterification replaces → FI08; reduces greenhouse gas emissions by up to 22% → FI08; Lecitase Ultra → FI08; Termamyl → FI10; Eversa → EN03; Lipura → I02; enzymatic esterification process → I02; Innova → EN02; Fiberex → EN02; Fortiva → EN02; JumpStart → A36; 80 million acres → A35, A36; replace a significant portion of chemical surfactants → I07; over half of the world's population → I07;
产品与服务
该公司未公开其产品或服务——我们可通过引荐了解。
商业模式 · role model
Novonesis is a global biotechnology company that produces enzymes, cultures, and probiotics for a wide range of industries, including food and beverages, human health, household care, and agriculture. It sells these performance biosolutions to business customers globally, earning revenue through direct sales and distribution channels. The company creates value by leveraging its proprietary microbial strain library and fermentation capabilities to provide solutions that improve product performance, sustainability, and efficiency for its clients.
| Biosolutions 2024 Novonesis operates through two main business segments: Food & Health Biosolutions and Planetary Health Biosolutions. “Our business is split into two divisions: Food & Health Biosolutions and Planetary Health Biosolutions.” | backend.novonesis.com weak (company, news, market research, other) |
| 2024 Novonesis reported pro forma sales of EUR 3,945.5 million in 2024. “Novonesis realized pro forma sales of EUR 3,945.5 million in 2024, of which Food & Health Biosolutions represented 45%, while Planetary Health Biosolutions represented 55%.” | backend.novonesis.com weak (company, news, market research, other) |
| 2024 The company achieved a pro forma adjusted EBITDA margin of 36.1% in 2024. “Pro forma adjusted EBITDA was EUR 1,423.4 mil lion in 2024, representing a pro forma adjusted EBITDA margin of 36.1%” | backend.novonesis.com weak (company, news, market research, other) |
| 2024 Novonesis reinvests approximately 11% of its sales into research and development. “In 2024, we reinvested close to 11% of our sales into research and development (R&D), as innovation is a critical long-term enabler to deliver impactful customer solutions.” | backend.novonesis.com weak (company, news, market research, other) |
| 2024 The company has accumulated nearly 10,000 patents. “With an annual investment of currently around EUR 400 million in research and development, we have accumulated nearly 10,000 patents, and we con sistently introduce a significant number of new products each year.” | backend.novonesis.com weak (company, news, market research, other) |
| 2024 The statutory merger between Novozymes A/S and Chr. Hansen Holding A/S was completed on January 29, 2024. “On January 29, 2024, the final regulatory approvals were obtained and the final registration of the statutory merger between Novozymes A/S (“Novozymes”) and Chr. Hansen Holding A/S (“Chr. Hansen”) was successfully …” | regnskaber.cvrapi.dk weak (company, news, market research, other) |
| Denimax® family The Denimax family of products replaces pumice stones in denim abrasion, reducing environmental impact and costs. “A small dose of this product can replace several kilograms of stones.” | www.novonesis.com weak (company, news, market research, other) |
| Eversa® Advance Eversa® Advance replaces acid esterification in biodiesel feedstock pretreatment, improving efficiency and sustainability. “With Eversa® Advance, biodiesel producers can replace acids with enzymes, ensuring a smooth plant throughput, reduced need for maintenance and methanol rectification, and a more sustainable process.” | www.novonesis.com weak (company, news, market research, other) |
| uhde® enzymatic esterification The enzymatic esterification process replaces traditional chemical catalysts like inorganic acids or metal-based catalysts in ester production. “The new enzymatic esterification process developed by thyssenkrupp Uhde leverages Novonesis’ bespoke enzymes as catalysts, replacing traditional chemical catalysts such as inorganic acids or metal-based catalysts.” | www.thyssenkrupp-uhde.com weak (company, news, market research, other) |
| Lipura® Split The enzymatic fat-splitting process using Lipura® Split replaces conventional thermal fat-splitting towers. “To address these challenges, Novonesis and thyssenkrupp Uhde are jointly launching an enzymatic fat-splitting process using the Novonesis Lipura® Split enzyme.” | www.novonesis.com weak (company, news, market research, other) |
| Multi-enzyme solutions 2014 Enzymes are used to replace phosphates (STPP) in laundry detergents to reduce environmental impact while maintaining cleaning performance. “The combination of modifying detergent compositions and using multienzyme solutions enables the detergent manufacturers to replace phosphates without compromising the cleaning performance.” | www.slideserve.com weak (company, news, market research, other) |
| Enzyme-based detergents 2025 Enzymes allow for washing at lower temperatures, which significantly reduces the energy consumption and carbon footprint associated with heating water. “One of the most significant advantages of using enzymes in detergents is their ability to catalyze biological reactions at lower temperatures.” | ml-eu.globenewswire.com weak (company, news, market research, other) |
状态
近期新闻 5
由自动检索获得；摘要为机器生成的英文。标题含公司名称，或摘要以该公司为主体——引用前请核对原文。
- 2026-09-22 Novonesis stock gains support from DKK 1 billion buyback ad-hoc-news.deNovonesis is supported by a large DKK 1 billion buyback, helping underpin a stock near the upper end of its 52-week range at around DKK 430.50, while brokers still see upside driven by earnings growth and margins despite the buyback.
- 2026-09-01 Efterspørgsel på mælkeprodukter driver vækst hos Novonesis | avisendanmark.dk avisendanmark.dkNovonesis is experiencing growth driven by rising demand for fresh, high-protein dairy products. The company is the merged entity of Chr. Hansen and Novozymes, headquartered in Lyngby.
- 2026-08-20 Novonesis beats expectations and raises guidance - Ritzau - Danish News in English powered by The Copenhagen Post danishnews.cphpost.dkNovonesis exceeded expectations in Q2, posting 1.116 billion euros in revenue and a quarterly profit of 179.4 million euros. The company raised its full-year organic revenue growth outlook to 7–8% (from 5–7%), driven by strong demand for biosolutions, especially in the food and …
- 2026-08-19 H1 2026: Novonesis delivered strong 8% organic sales growth and increases full-year outlook | Novonesis novonesis.comNovonesis posted strong H1 2026 results with 8% organic sales growth (9% in Q2) and an EBITDA margin of 37.7%, and raised its full-year outlook to 7–8% organic growth with margins at the high end of 37–38%, plus an inaugural €1 billion multi-year share buyback and progress on …
- 2026-08-04 Novonesis vokser, mens rivaler kæmper: Her er direktørs forklaring borsen.dkNovonesis is growing faster than expected, driven by strong sales growth in several new markets, despite skepticism and weaker results from competitors.
论坛亮相
- 活动
- BIO Innovations North America World Bio Markets
- 年份
- 2021–2026年
该公司列于这些活动的议程或参会名单中；这既不代表认可，也不构成排名。 数据来源与方法 →
关系网络：股东、合作伙伴、同类
同类企业
AB Enzymes · c-LEcta GmbH · Solyve · BiCT srl - Biological and Chemical Technologies · Biocatalysts Ltd · enginzyme · SternEnzym · Enzymicals AG
公司信息
注册编号
- Novozymes A/S reg. no.: 10007127
融资
- 最近一轮: Debt financing · 2026-03-01
来自自动化调研（公司网站、公告、商业企业数据库），未经人工核对。注册编号请以官方登记为准。
身份与联系方式
联系方式、人员和法律信息仅向会员开放。
会员登录